| Literature DB >> 29784860 |
Ulrich J Sachs1, Sentot Santoso2, Piyapong Simtong3,1, Amornrat V Romphruk4, Annalena Traum1, Monika Burg-Roderfeld1,5, Gregor Bein1, Konstantin Jakubowski1, Andreas Dominik6, Michael Theisen7,8, Ikhlaq Hussain Kana8.
Abstract
The Fcγ receptor IIIb (FcγRIIIb) is a low-affinity receptor of IgG and is essential in neutrophil-mediated effector functions. Different allelic forms of FcγRIIIb carrying human neutrophil antigen (HNA-1a, -1b, -1c, and -1d) have been identified. Here, we have generated stable transfected HEK293 cell lines expressing HNA-1aa, -1bb, and -1bc. Of these, cells expressing HNA-1bc interacted significantly stronger (binding affinities, 2.277 versus 0.743) with human IgG than cells expressing the HNA-1aa or -1bb alloforms. The higher affinity of IgG toward the HNA-1c alloform was confirmed using neutrophils derived from German blood donors. Neutrophils from HNA-1abc-phenotyped individuals bound IgG significantly stronger (1.825 versus 0.903) than did neutrophils from HNA-1ab-typed individuals. These findings were confirmed by surface plasmon resonance (SPR) analysis demonstrating that recombinant HNA-1bc had a higher affinity (dissociation constant [Kd ], 7.24 × 10-6 M) than recombinant HNA-1bb (Kd , 1.15 × 10-5 M) against normal IgG. Finally, we demonstrated that Plasmodium falciparum merozoites opsonized with human IgG affinity purified against P. falciparum glutamate-rich protein (GLURP) enhanced stronger reactive oxygen species (ROS) emission in neutrophils obtained from HNA-1abc donors than in neutrophils from HNA-1ab donors. Collectively, these results indicate that the amino acid substitution Ala78Asp resulting in the HNA-1c allotype leads to higher affinity toward human IgG, enhancement of neutrophil activation, and possibly effective clearance of malaria by intracellular ROS.Entities:
Keywords: IgG binding; alloantibodies; human neutrophil antigen-1; malaria
Mesh:
Substances:
Year: 2018 PMID: 29784860 PMCID: PMC6056857 DOI: 10.1128/IAI.00924-17
Source DB: PubMed Journal: Infect Immun ISSN: 0019-9567 Impact factor: 3.441